Inflammatory Bowel Disease Treatment Market Size, Share & Industry Analysis, By Disease Indication (Ulcerative Colitis and Crohn�s Disease), By Route of Administration (Oral and Injectables), By Drug Class (IL Inhibitors, TNF Inhibitors, Anti-integrin, JAK Inhibitors, Corticosteroids, ASA Drugs, and Others), By Distribution Channel (Hospital Pharmacy and Retail Pharmacy & Other), and Regional Forecast, 2024-2032

ATTRIBUTE

DETAILS

Study Period

2019-2032

Base Year

2023

Estimated Year

2024

Forecast Period

2024-2032

Historical Period

2019-2022

Growth Rate

CAGR of 5.8% from 2024 to 2032

Unit

Value (USD billion)

Segmentation

By Disease Indication

• Ulcerative Colitis
• Crohn's Disease

By Route of Administration

• Oral
• Injectables

By Drug Class

• IL Inhibitors
• TNF Inhibitors
• Anti-integrin
• JAK Inhibitors
• Corticosteroids
• ASA Drugs
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy & Other

By Geography

• North America (By Disease Indication, By Route of Administration, By Drug Class, By Distribution Channel, and By Country)
  • U.S. (By Disease Indication)
  • Canada (By Disease Indication)
• Europe (By Disease Indication, By Route of Administration, By Drug Class, By Distribution Channel, and By Country)
  • U.K. (By Disease Indication)
  • Germany (By Disease Indication)
  • France (By Disease Indication)
  • Italy (By Disease Indication)
  • Spain (By Disease Indication)
  • Scandinavia (By Disease Indication)
  • Rest of Europe (By Disease Indication)
• Asia Pacific (By Disease Indication, By Route of Administration, By Drug Class, By Distribution Channel, and By Country)
  • China (By Disease Indication)
  • Japan (By Disease Indication)
  • India (By Disease Indication)
  • Australia (By Disease Indication)
  • Southeast Asia (By Disease Indication)
  • Rest of Asia Pacific (By Disease Indication)
• Latin America (By Disease Indication, By Route of Administration, By Drug Class, By Distribution Channel, and By Country)
  • Brazil (By Disease Indication)
  • Mexico (By Disease Indication)
  • Rest of Latin America (By Disease Indication)
• Middle East & Africa (By Disease Indication, By Route of Administration, By Drug Class, By Distribution Channel, and By Country)
  • GCC (By Disease Indication)
  • South Africa (By Disease Indication)
  • Rest of MEA (By Disease Indication)